SCHEMBL10205062

SCHEMBL10205062

Cc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(NCc2cccc3c2C(C)(C)C(=O)N3)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 19/20 0.49
▸ EGFR P00533 2/20 0.49
▸ INSR P06213 3/20 0.47
▸ KCNH2 Q12809 2/20 0.47
▸ PLK4 O00444 1/20 0.47
▸ BUB1B O60566 1/20 0.47
▸ JAK2 O60674 1/20 0.47
▸ ROCK2 O75116 1/20 0.47
▸ ABL1 P00519 1/20 0.47
▸ NTRK1 P04629 1/20 0.47
▸ LCK P06239 1/20 0.47
▸ NPM1 P06748 1/20 0.47
▸ FES P07332 1/20 0.47
▸ LYN P07948 1/20 0.47
▸ RET P07949 1/20 0.47
▸ IGF1R P08069 1/20 0.47
▸ ABCB1 P08183 1/20 0.47
▸ MET P08581 1/20 0.47
▸ ROS1 P08922 1/20 0.47
▸ FGR P09769 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10205063 0.93 ALK (0.47) ALKEGFRINSRKCNH2PLK4
SCHEMBL10206174 0.90 WEE1 (0.49) ALKEGFRINSRKCNH2PLK4
SCHEMBL10205156 0.90 EGFR (0.47) ALKEGFRINSRKCNH2PLK4
SCHEMBL10206122 0.90 ALK (0.48) ALKEGFRFLT3PTK2PTK2B
SCHEMBL10205064 0.89 ALK (0.42) ALKEGFRINSRKCNH2PLK4
SCHEMBL10206638 0.87 ALK (0.42) ALKINSRKCNH2IGF1RFLT3
SCHEMBL10206156 0.86 ALK (0.48) ALKEGFRINSRKCNH2NTRK1
SCHEMBL10205075 0.86 STK17A (0.40) ALKEGFRINSRKCNH2PLK4
SCHEMBL16255659 0.85 EGFR (0.48) ALKEGFRINSRKCNH2NTRK1
SCHEMBL14331595 0.84 STK17A (0.58) EGFRNTRK1METKDRPTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2655358-B1 OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2014-11-19 — — EP disclosed
US-8546443-B2 Benzylic oxindole pyrimidines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-01 — — US disclosed
US-20120329771-A1 BENZYLIC OXINDOLE PYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-27 — — US disclosed
WO-2012085126-A1 OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329771-A1 BENZYLIC OXINDOLE PYRIMIDINES MKI67, CCNI, CCNB1 ALK 2575/4885EGFR 1397/4885INSR 1352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback